Table 2.

Relationship between serum miR-135 and miR-20a expression and clinical characteristics in patients with gastric cancer [(‾χ ± s), U/mL]

Clinical characteristic	Cases (n)	miR-135 expression	P	miR-20a expression	P
Gender			> 0.05		> 0.05
M	97	7.56 ± 0.57		6.56 ± 0.85
F	49	7.43 ± 0.54		6.48 ± 0.83
Age (years)			> 0.05		> 0.05
< 60	88	7.98 ± 0.67		6.64 ± 0.76
≥ 60	58	8.16 ± 0.69		6.72 ± 0.81
Degree of gastric cancer progression			< 0.01		< 0.01
Early stage	54	7.96 ± 0.32		5.08 ± 0.46
Progressive phase	92	9.11 ± 0.34		7.23 ± 0.41
TNM stage			< 0.01		< 0.01
I-II	76	7.24 ± 0.26		4.93 ± 0.37
III-IV	70	9.36 ± 0.28		7.51 ± 0.42
Degrees of differentiation			< 0.01		< 0.01
Well differentiated	94	7.78 ± 0.34		5.56 ± 0.42
Poorly differentiated	52	9.36 ± 0.41		7.38 ± 0.47
Lymph node metastasis			< 0.01		< 0.01
No	65	7.43 ± 0.27		5.13 ± 0.49
Yes	81	9.27 ± 0.32		7.44 ± 0.46
Distant metastasis			< 0.01		< 0.01
Yes	53	7.51 ± 0.45		5.34 ± 0.66
No	93	9.43 ± 0.53		7.63 ± 0.72